dr. ting xu, founder, chairman and ceo of alphamab oncology won the sixth “suzhou outstanding talent award”. on july 10, the award ceremony was held at the opening of the 12th suzhou international elite venture week and the 1st suzhou scientists day. mr. yaping li, mayor of suzhou and deputy suzhou municipal party secretary presented the award certificate to dr. xu ting.
the "suzhou outstanding talent award" is the highest talent award established by the suzhou municipal party and government. it is awarded once every three years to various outstanding talents who have made significant contribution to economic and social development. in the award speech to dr. xu ting, the presenter commented: “life-saving medicine, made in china; to address the need for oncology medicine. you are not a “god of medicine”, but you are a pioneer to develop life-saving medicine , shining brightly in the "drug valley."
in 2008, dr. xu ting returned to china with the intention of "bridging the major domestic drug gap" to establish alphamab oncology, led the team to establish a fully integrated proprietary biologics medicine development platforms. three drug candidates were selected as national major novel drug innovation special projects. he has been leading the biosimilar sector in china, playing an important leading role in the development of biopharmaceuticals in china. over the past 12 years, dr. xu ting has always focused on "making cancer a controllable and curable disease to improve the quality of life through innovative drugs". he has achieved excellent track record due to his outstanding innovation capabilities . dr. xu ting has successively won the "suzhou charismatic science and technology figure", "mayor’s award for science and technology innovation and entrepreneurship in suzhou" and " top ten talent award for innovation and entrepreneurship in jiangsu province".
alphamab oncology forward-looking statements
this press release contains statements related to our future business and financial performance and future events or developments involving alphamab oncology that may constitute forward-looking statements. these statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. these statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. we may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. in addition, our representatives may from time to time make oral forward-looking statements. such statements are based on the current expectations and certain assumptions of alphamab oncology’s management and business operation, many of which are difficult to predict and generally beyond alphamab oncology’s control. these are subject to a number of risks and uncertainties, including but not limited to, uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, alphamab oncology's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding and alphamab oncology’s disclosures. should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of alphamab oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. other than as required by applicable law, alphamab oncology undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.